ArticleJournal for immunotherapy of cancer2025

Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry.

Alessio Cortellini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.